Stability of the 13C column separation in industrial mode of operation
Based on the original cryogenic column conceived and built by National Institute for Research and Development of Isotopic and Molecular Technologies Cluj-Napoca, it is necessary to implement control algorithms for the industrial mode of operation of this equipment, in order to produce some chemical compounds with higher concentration in (13C), compounds asked in various domains. The present work deals with column efficiency analysis and stability in industrial mode of operation.
Electrical power monitoring and control in 13C isotope separation column boiler
One of the main elements of a cryogenic (13C) separation column is the boiler. The control of the power supply which feeds the boiler's resistance is of major importance. In order to ensure a safe and stable operation of the plant, a monitoring and control unit is designed using NI PXI-8183 process computer. The developed LabVIEW™ application implements a PI controller and also data logging. Step response and disturbance rejection test are carried out to prove the feasibility of the design.
Pharmacokinetics and Metabolism of 14C-Brivaracetam, a Novel SV2A Ligand, in Healthy Subjects
This study was designed to investigate the human absorption, disposition, and mass balance of 14C-brivaracetam, a novel high affinity SV2A ligand with potent anticonvulsant activity. Six healthy male subjects received a single p.o. dose of 14C-brivaracetam (150 mg, 82 μCi, or 3.03 MBq). Serial blood and complete urine and feces were collected until 144 h postdose. Expired air samples were obtained until 24 h. Brivaracetam was rapidly absorbed, with Cmax of 4 μg/ml occurring within 1.5 h of dosing. Unchanged brivaracetam amounted to 90% of the total plasma radioactivity, suggesting a modest first-pass effect. Plasma protein binding of radioactivity was low (17.5%). Urinary excretion exceeded 90% after 2 days, and the final mass balance reached 96.8% of the radioactivity in urine and 0.7% in feces. Only 8.6% of the radioactive dose was recovered in urine as unchanged brivaracetam, the remainder being identified as non–cytochrome P450 (P450)- and P450-dependent biotransformation products resulting from hydrolysis of the amide moiety (M9, 34.2%), hydroxylation of the n-propyl side chain (M1b, 15.9%), and a combination of these two pathways leading to the hydroxy acid (M4b, 15.2%). Minor amounts of taurine and glucuronic acid conjugates and other oxidized derivatives were also identified. Brivaracetam is completely absorbed, is weakly bound to plasma proteins, extensively biotransformed through several metabolic pathways, and eliminated renally.